Washington State University
researchers released results from three studies that strongly suggest that
Glyco-Flex III, an animal health product formulated by Vetri-Science
Laboratories of Vermont, is a safe and beneficial option for use in dogs
requiring joint support.
An estimated 14 million dogs suffer from joint problems, which is the
sixth-leading cause for which dog owners seek veterinary treatment for
their pets.
"We're pleased that a respected institution like Washington State
University has expanded the scientific research available on the benefits
of Glyco-Flex," said Dale R. Metz, CEO of FoodScience Corporation, the
parent company of Vetri-Science. "Researchers continue to confirm what
we've known for more than two decades: Glyco-Flex offers an excellent
non-pharmaceutical option for animals in need of joint support."
Steven A. Martinez, DVM, MS, Dipl. ACVS, with the university's College
of Veterinary Medicine, and Jaime A. Yanez, a Ph.D. candidate in the
university's College of Pharmacy, presented the results at an opening
session of the 2007 North American Veterinary Conference (NAVC), one of the
profession's largest continuing education programs serving all veterinary
professionals.
As non-pharmaceutical treatment of joint conditions in humans has grown
in prevalence, veterinary medicine began applying some of the lessons
learned in treating human joint conditions. In 1981, Vetri-Science, a
leader in research and product development of high-quality supplements for
large and small animals, developed Glyco-Flex. Glyco-Flex is a proprietary
health product for dogs, cats and horses containing ingredients clinically
proven to promote joint and connective tissue health.
First study shows improved movement in dogs using Glyco-Flex III
In a randomized, double-blind, cross over design dog study, a stifle
osteoarthritis (OA) model was used to determine if Glyco-Flex III could
reduce cartilage breakdown and help normalize joint function. The results
of the study suggest that Glyco-Flex III may reduce the severity of
cartilage breakdown and synovitis, and help normalize joint function in
dogs with stifle joints affected by OA.
Other studies confirms Glyco-Flex III's anti-inflammatory and
antioxidant properties
In the second WSU study, canine chondrocytes were used in cell culture
experiments to assess the effects of Glyco-Flex III tablets on key markers
of inflammation. Glyco-Flex III tablets showed positive reductions in
nitric oxide (NO), soluble collagen, tumor necrosis factor-alpha, IL-6,
PGE(2) and matrix metalloproteinase-3 (MMP-3), which are key markers of
inflammation.
Thus, Glyco-Flex III appears to reduce cartilage breakdown, inhibit
cytokine- induced NO and PGE(2) production, and reduce proteolytic
breakdown.
In the third WSU study, canine chondrocytes were used in cell culture
experiments to assess the effects of the main active constituents in Glyco-
Flex III on key markers of inflammation. These key ingredients - Perna
canaliculus, glucosamine, MSM, DMG and grape seed extract - showed positive
reductions in NO, soluble collagen, tumor necrosis factor-alpha, IL-6,
PGE(2) and MMP-3, which are key markers of inflammation. They also appear
to reduce cartilage breakdown, inhibit cytokine-induced NO and PGE(2)
production and reduce proteolytic breakdown.
These latter two in vitro studies demonstrate some of the key pathways
and mechanisms by which the main components of Glyco-Flex III may function
in the joint. The results also suggest that Glyco-Flex III and its active
components have anti-inflammatory and antioxidant properties.
Glyco-Flex also tested for safety
The WSU studies bring to 14 the number of Vetri-Science-sponsored
research studies that have been conducted at leading universities and by
independent researchers exploring the safety and benefits of Glyco-Flex.
Studies have been conducted measuring everything from veterinarians'
satisfaction with Glyco- Flex to the documented presence of
anti-inflammatory agents in the supplement.
One in vivo study evaluated Glyco-Flex's safety, even when given to
animals at doses much higher than ordinarily recommended. In this clinical
trial, Glyco-Flex III was fed to a treatment group of dogs for 56 days.
Blood and urine tests performed on the treated dogs were all within the
normal ranges and were consistent between groups in each phase of the
study. The dogs' appetites and weights also were unchanged.
Summaries of all the studies are detailed in a brochure titled
"Glyco-Flex and Its Active Ingredients: Clinical and Research Studies",
which is available from the company or any Vetri-Science Sales
Representative or distributor.
The Glyco-Flex difference
Glyco-Flex contains a unique combination of GlycOmega(TM) (Perna
canaliculus from an exclusive New Zealand source) plus DMG, Glucosamine,
MSM and other active ingredients that have been proven beneficial for dogs
requiring joint support. Significantly, it is the only clinically
researched, Perna-based joint support product available.
Perna canaliculus, commonly known as the New Zealand green-lipped
mussel, is a natural source of glycosaminoglycans (including
chondroitin-4 and -6 sulfates and hyaluronic acid), minerals, amino
acids and omega 3 fatty acids - compounds that can make a significant
contribution to canine mobility and comfort. Only Glyco-Flex products
are formulated with GlycOmega(TM) Perna. Unlike Perna extract-based
products and mussel powders which lack important fatty acids and other
bioactive components (e.g. defatted powders or extracts), in Glyco-Flex
the entire organism is utilized, resulting in higher levels of anti-
inflammatory activity. Moreover, a balanced blend of ingredients is
then available to the patient in the same relative proportions as they
occur in nature.
Dimethylglycine (DMG) is a naturally occurring compound that has been
shown to support joint structure and function. Studies also indicate
that DMG acts as a powerful antioxidant to help promote healthy joints
and connective tissues. Four U.S. patents have been awarded to Vetri-
Science Laboratories based on over twenty years of research into the
properties of DMG.
Glucosamine hydrochloride is an ingredient clinically proven to promote
canine joint health. The glucosamine used in all Glyco-Flex products is
guaranteed to be 99% pure. Every lot is tested for quality to ensure
patients receive the highest quality, human-grade glucosamine available.
Methylsulfonylmethane (MSM) has been demonstrated to provide hip and
joint support. The MSM used in Glyco-Flex products is guaranteed to be
99% pure. Every lot is tested for quality to ensure patients receive the
highest quality, human-grade MSM available.
NOTE:
Glyco-Flex is an animal health product. Vetri-Science does not
purport that Glyco-Flex cures, mitigates, treats or prevents any disease.
The conclusions reached in these studies are the observations of
independent researchers and as such, should not be misconstrued as a claim
made by Vetri- Science regarding the benefits of Glyco-Flex. These studies
were conducted to better understand scientifically how the product and
ingredients work, not to support any claim.
ABOUT VETRI-SCIENCE
For more than 25 years, Vetri-Science Laboratories of Vermont has been
a leader in research and product development of high-quality supplements
for large and small animals. A division of FoodScience Corporation,
Vetri-Science is headquartered in Essex Junction, Vermont, and produces
only the purest, most reliable products to meet the exacting standards of
today's veterinarians as well as dog, cat and horse owners.
Vetri-Science
vetriscience/
Комментариев нет:
Отправить комментарий